In 278 patients with locally advanced non-nasopharyngeal head and neck squamous cell carcinoma (272 analysed), weekly cisplatin 40 mg/m² with radiation was noninferior to 3-weekly 100 mg/m² for 2-year locoregional control (61.3% vs 51.1%), with fewer grade ≥3 adverse events.
RCTn = 278
Sharma et al. Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neck